Compare Conagra Brands Inc (CAG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Novo Nordisk A/S — how do they compare? Conagra Brands Inc trades at $14.04 (market cap $6.77B), while Novo Nordisk A/S trades at $50.94 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 31.7× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (9.89%). Which is the better fit depends on your goals.
| CAG | NVO | |
|---|---|---|
Market Cap | $6.77B | $214.94B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $71.70 |
52-Week Low | $12.58 | $35.29 |
Enterprise Value | $14.05B | $233.91B |
Dividend Yield | 9.89% | 3.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
